HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Topotecan is anti-angiogenic in experimental hepatoblastoma.

AbstractBACKGROUND:
Advanced hepatoblastoma often is lethal despite current therapies, yet development of novel approaches has been hampered by the lack of biologically relevant models. One new strategy selectively targets endothelium rather than tumor cells using frequently administered, low-dose ("metronome") chemotherapy. Metronome topotecan has antiangiogenic activity in some experimental tumors. The authors developed a xenograft model of human hepatoblastoma to test the effect of metronome topotecan in this system.
METHODS:
Xenografts resulted from intrarenal injection of cultured human hepatoblastoma cells in athymic mice. Topotecan (0.36 mg/kg/dose) or vehicle was injected intraperitoneally 5 times per week. At week 6, 10 control/treated mice were killed, and remaining animals were maintained without treatment until week 8. Tumor weights were compared by Kruskal-Wallis analysis, and vascular alterations were ascertained by specific immunostaining.
RESULTS:
Metronome topotecan affected tumor weights in a delayed fashion: weights were diminished significantly only at 8 weeks (treated v control: 6 weeks, 0.59 g v 82 g, P value, not significant; 8 weeks, 1.13 g v 3.82; P <.02). Decreased vascularity and increased endothelial cell apoptosis were observed in treated xenografts.
CONCLUSIONS:
Metronome topotecan inhibits growth and neovascularization in experimental hepatoblastoma. The durability of this effect is novel and has not been observed in other xenograft tumor models. Cytotoxic targeting of endothelial cells may hold particular promise for therapy of children with advanced hepatoblastoma.
AuthorsKimberly W McCrudden, Akiko Yokoi, Amit Thosani, Samuel Z Soffer, Eugene S Kim, Jianzhong Huang, Christina Manley, Kathleen O'toole, Darrell J Yamashiro, Jessica J Kandel, William Middlesworth
JournalJournal of pediatric surgery (J Pediatr Surg) Vol. 37 Issue 6 Pg. 857-61 (Jun 2002) ISSN: 1531-5037 [Electronic] United States
PMID12037749 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2002, Elsevier Science (USA). All rights reserved.
Chemical References
  • Angiogenesis Inhibitors
  • Topotecan
Topics
  • Angiogenesis Inhibitors (pharmacology)
  • Animals
  • Female
  • Hepatoblastoma (blood supply, drug therapy, pathology)
  • Humans
  • Liver Neoplasms, Experimental (drug therapy, pathology, physiopathology)
  • Lung Neoplasms (secondary)
  • Mice
  • Mice, Nude
  • Neovascularization, Pathologic (pathology)
  • Topotecan (pharmacology)
  • Transplantation, Heterologous
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: